1. Clinical Overview of KPV

Molecule: Three–amino acid anti-inflammatory peptide fragment from α-MSH · Sequence: Lys–Pro–Val

Classification: Potent anti-inflammatory, anti-microbial, and epithelial healing peptide with extremely low toxicity.

Physiologic Significance: Primary immunomodulatory sequence of α-MSH — cytokine suppression, epithelial barrier restoration, antimicrobial defense, mast-cell/eosinophil downregulation, GI protection. Unlike full-length α-MSH, KPV does not cause pigmentation.

2. Mechanisms of Action

2.1 NF-κB Suppression

Downregulates NF-κB, TNF-α, IL-1β, IL-6, IL-8, mast-cell activation. Broad-spectrum, non-immunosuppressive.

2.2 Epithelial Barrier Repair

Restores tight junction proteins (occludin, claudins, ZO-1), GI/dermal barrier integrity, mucosal function.

2.3 Antimicrobial Activity

Effects against S. aureus, MRSA, fungal/yeast species, gut dysbiosis pathogens.

2.4 Melanocortin System Modulation

Selectively activates MC1R and MC3R without pigmentation or melanocyte activation.

3. Evidence Summary — Clinical Domains

3.1 GI & IBD-Related

Reduces colonic inflammation, repairs epithelial barrier, decreases GI permeability. Ideal for IBS/IBD, stress-related gut inflammation, post-antibiotic recovery, SIBO, post-GLP-1 barrier repair.

3.2 Dermatologic & Aesthetic

Eczema, dermatitis, acne, rosacea, atopic flares, psoriasis (adjunct). Post-procedure: reduces erythema, speeds barrier recovery, decreases PIH risk.

3.3 Systemic Inflammatory Disorders

MCAS, histamine intolerance, exercise-induced inflammation, chronic low-grade inflammation, long-haul fatigue.

3.4 Wound Healing & Post-Surgical

Reduces excessive inflammation, local cytokine storms, abnormal scarring.

3.5 Immunomodulation without Immunosuppression

Unlike steroids, KPV does not suppress immunity, blunt healing, increase infection risk, or raise cortisol.

4. Administration Routes & Protocols

4.1 Oral KPV

Standard: 250–500 mg/day · Therapeutic: 500–1,000 mg/day · Severe: 1,000–1,500 mg/day
Cycle: Daily × 8–12 weeks · May continue long-term

4.2 Topical KPV

Concentration: 0.1–1% in gel/cream/serum · 1–2×/day · Optional pairing with GHK-Cu serum

4.3 Injectable / SC KPV

Dose: 1–3 mg SC daily or 3–5 mg SC 2–3×/week · Duration: 4–12 weeks

4.4 Rectal Suppository

Dose: 5–10 mg rectally, 1–2×/day · For UC, proctitis, post-antibiotic GI dysfunction

5. Clinical Decision Trees

Decision Tree 1 — Route Selection

GI inflammation? → Oral + Rectal KPV

Dermatitis/acne/rosacea/aesthetic? → Topical ± oral

Systemic inflammation/MCAS? → SC + oral KPV

Long-haul/chronic fatigue? → Oral KPV ± NAD+ ± Glutathione

Severe post-procedure? → Topical + oral KPV

Decision Tree 2 — KPV vs. BPC-157 vs. TB-500

Primary GI/immune inflammation? → KPV

Primary musculoskeletal injury? → TB-500 + BPC-157

Mixed inflammation + injury? → KPV + BPC-157

Dermal/aesthetic recovery? → KPV topical + GHK-Cu

6. Integrated Treatment Archetypes

Archetype A — GI Healing & IBD/IBS

Systemic: KPV oral 500–1,000 mg/day + RECOVER™ 1 cap AM + Glutathione

Local: KPV suppository 5–10 mg nightly

Outcome: Barrier repair + inflammation control + epithelial healing.

Archetype B — Dermatologic & Aesthetic

Topical: KPV 0.1–1% serum 2×/day + GHK-Cu nightly

Systemic: KPV oral 250–500 mg/day

Outcome: Reduced redness, irritation, PIH, improved recovery.

Archetype C — MCAS / Histamine Intolerance

Systemic: KPV SC 1–3 mg daily/QOD + KPV oral 500 mg/day + RECOVER™

Adjuncts: Low-histamine diet + antihistamines PRN

Archetype D — Post-Surgical / High-Output Inflammation

Systemic: KPV SC 2–3 mg daily × 1–2 weeks + Glutathione IV + BPC-157

Topical: KPV gel to incision once healed

7. Expected Clinical Timeline

48–72 hours: Reduced inflammation/redness/GI discomfort
1–2 weeks: Noticeable dermatitis/GI improvement
4–6 weeks: Significant barrier repair + immune stabilization
8–12 weeks: Full therapeutic benefit

8. Contraindications

Absolute

Known hypersensitivity

Relative

Pregnancy
Lactation
Active cancer (case-by-case)
Severe autoimmune instability

9. Adverse Effects

Rare and mild: temporary nausea, mild headache, injection site tenderness, loose stools at high oral doses.

10. Monitoring

Symptom tracking
Inflammation markers (CRP, ESR)
GI symptom scales
Dermatologic response
MCAS triggers and patterns

Legal Disclaimer

This document is provided solely for educational and informational purposes. KPV and other peptides referenced herein are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable for any damages or adverse outcomes. Use at your own risk.

References — KPV Clinical Reference Guide

Foundational Melanocortin & α-MSH

1. Cone, R. D. The melanocortin system. Endocrine Reviews, 27(7), 736–749 (2006).

2. Catania, A., et al. Melanocortin peptides and anti-inflammatory signaling. Nat Rev Drug Discov, 3(12), 903–916 (2004).

3. Lipton, J. M., & Catania, A. Anti-inflammatory actions of α-MSH. Brain Behav Immun, 5(3), 282–289 (1991).

KPV-Specific Anti-Inflammatory

4. Getting, S. J., et al. KPV suppresses inflammation independently of melanocortin receptors. J Immunol, 166(4), 2723–2729 (2001).

5. Eberle, A. N. Melanocortin peptide fragments. Peptides, 9(3), 411–417 (1988).

6. Rajora, N., et al. Anti-inflammatory effects of KPV. J Leukocyte Biol, 63(2), 198–203 (1998).

7. Singh, M., et al. KPV inhibits NF-κB activation. Inflamm Res, 48(10), 533–540 (1999).

Skin, Dermatology & Wound Healing

8. Cutuli, M., et al. KPV accelerates wound healing. J Invest Dermatol, 113(2), 308–313 (1999).

9. Getting, S. J., et al. KPV protects epithelial cells. Br J Pharmacol, 137(5), 697–704 (2002).

10. Brzoska, T., et al. Melanocortins in skin inflammation. J Invest Dermatol, 126(8), 1936–1945 (2006).

11. Bohm, M., et al. Anti-inflammatory skin effects of melanocortins. Exp Dermatol, 13(S4), 15–26 (2004).

GI Mucosal Healing & Barrier

12. Maaser, C., et al. KPV reduces experimental colitis. Inflamm Bowel Dis, 12(7), 612–620 (2006).

13. Wei, N., et al. KPV improves intestinal restitution. Am J Physiol GI Liver Physiol, 291(3), G528–G538 (2006).

14. Chen, Y., et al. Melanocortin peptides suppress mucosal inflammation. World J Gastroenterol, 12(37), 5936–5942 (2006).

15. Kaleta, B., et al. Oral/topical KPV attenuates gut inflammation. Peptides, 27(8), 2094–2102 (2006).

Immunology & Systemic Inflammation

16. Bednarek, M. A., et al. Melanocortin tripeptide structure–activity. Biochem Biophys Res Commun, 217(3), 903–910 (1995).

17. Holzer, P., & Reichmann, F. Neurogenic inflammation modulation. Physiol Rev, 99(1), 155–202 (2019).

18. Taherzadeh, S., et al. KPV prevents endotoxin-induced inflammation. Cytokine, 26(1), 1–8 (2004).

19. Huang, L., et al. Melanocortin peptides inhibit ROS. Free Radic Biol Med, 42(5), 581–589 (2007).

Antimicrobial & Microbiome

20. Singh, G., et al. Antimicrobial effects of melanocortin tripeptides. J Antimicrob Chemother, 60(6), 1307–1313 (2007).

21. Eves, P. C., et al. Immune–microbiome interactions. Immunol Cell Biol, 87(1), 34–40 (2009).

Pain & Neurological

22. Catania, A., et al. Melanocortin system in inflammation and pain. Trends Mol Med, 16(10), 434–442 (2010).

23. Ho, J. W., et al. Melanocortin peptides reduce neuropathic inflammation. J Neuroinflammation, 8, 117 (2011).

Regenerative & Tissue-Repair

24. Kalden, D. H., et al. KPV enhances fibroblast migration. Peptides, 31(12), 2179–2187 (2010).

25. Getting, S. J., et al. α-MSH fragments promote survival via PI3K–Akt. J Pharmacol Exp Ther, 306(2), 631–637 (2003).

KPV (Lysine–Proline–Valine Tripeptide)